Shopping Cart
- Remove All
- Your shopping cart is currently empty
Samalizumab (ALXN 6000), a humanized monoclonal antibody, selectively targets and inhibits the interaction between CD200 and its receptor (CD200R). This compound is utilized in the research of multiple myeloma and B-cell chronic lymphocytic leukemia [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Samalizumab (ALXN 6000), a humanized monoclonal antibody, selectively targets and inhibits the interaction between CD200 and its receptor (CD200R). This compound is utilized in the research of multiple myeloma and B-cell chronic lymphocytic leukemia [1]. |
In vitro | Samalizumab has been rationally designed featuring an IgG2/G4 constant region to minimize effector functions and preserve immune cell subpopulations. It is a recombinant humanized anti-CD200 monoclonal antibody intended to abrogate effector functions. Samalizumab specifically binds to the immune checkpoint CD200, blocking receptor engagement and signaling, and antagonizes CD200-driven immune suppression, thus mediating an anti-tumor immune response [1]. |
Alias | ALXN 6000 |
Cas No. | 1073059-33-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.